Industries > Pharma > Global Graft versus Host Disease (GVHD) Market 2019-2029

Global Graft versus Host Disease (GVHD) Market 2019-2029

Acute, Chronic and Prophylaxis GVHD

PUBLISHED: 04 April 2019
PAGES: 162
PRODUCT CODE: PHA0384
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE
SKU: PHA0384 Categories: , Tags: ,

The global graft versus host disease market is expected to grow at a CAGR of 7% from 2016-2021 and CAGR of 3% from 2019-2029. The market is expected to grow at a CAGR of 6% from 2016 to 2027. The market is estimated at $0.36bn in 2016, $0.51bn in 2021, and $0.64bn in 2026.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 162-page report you will receive 62 tables and 76 figures – all unavailable elsewhere.

The 162-page report provides clear detailed insight into the Graft versus Host Disease market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

• Revenue and growth forecasts to 2027 for the global GVHD market

• Revenue and growth forecasts to 2027 for the leading countries

• GVHD patient number forecast to 2027 per leading country, segmented into total allogenic cases, first allogenic cases, acute GVHD and chronic GVHD

• Revenue and growth forecasts to 2027 for the leading segments of the GVHD market by treatment type

• Revenue and growth forecasts to 2027 for the leading drugs in the GVHD market.

Global Graft versus Host Disease (GVHD) Market 2017-2027

Individual revenue forecasts to 2027 by treatment type:
• Prophylaxis GVHD
• Chronic GVHD
• Acute GVHD

Individual revenue forecasts to 2027 by product:

• Corticosteroids
– Methylprednisolone
– Budenofalk (effeverscent)

• ATG therapies
– Available ATG therapy (Thymoglobulin)
– Atege-Fresenius

• IL2Rα (CD25) inhibitors
– Simulect (Basiliximab)
– Leukotac (inolimomab)

• TNFα inhibitors
– Remicade (Infliximab)
– Enbrel (Etanercept)
– Co-stimulatory blockers
– Orencia (abatacept)
– Nulojix (belatacept)

• Other biologics
– Lemtrada (Alemtuzumab)
– Rituxan/MabThera (rituximab)
– Begedina (bt/9 anti-CD26)

• Calcineurin inhibitors
– Cyclosporine

• mTOR inhibitors
– Rapamune (sirolimus)
– Certican (everolimus)

• SOT therapies
– CellCept/Myfortic (mycophenolate mofetil)
– Prograf (tacrolimus)

• Anti-neoplastic therapies
– Velcade (bortezomib)
– Gleevec (imatinib)
– Methrotrexate
– Nipent (pentostatin)
– Cyclophosphamide

• Stem Cell Treatments
– In situ preparations of mesenchymal cells
– Prochymal (remestemcel-L)

• Extracorporeal Photophoresis
– Uvadex (Therakos)

Individual revenue forecasts to 2027 by country, further segmented by treatment type and by product:
• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

GVHD patient number forecasts to 2027 per leading country, segmented into:
• total allogenic cases
• first allogenic cases
• acute GVHD
• chronic GVHD

Visiongain’s study is intended for anyone requiring commercial analyses for the GVHD market. You find data, trends and predictions.

Buy our report today Global Graft versus Host Disease (GVHD) Market 2019-2029: Acute, Chronic and Prophylaxis GVHD.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Graft versus Host Disease (GVHD) Market 2019-2029


Download sample pages

Complete the form below to download your free sample pages for Global Graft versus Host Disease (GVHD) Market 2019-2029


Latest Pharma news

“Global Influenza Vaccines Market Set to Grow to $4.9bn by 2024” says new Visiongain report

The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market.

05 July 2019

READ

“Pharmaceutical Wholesale & Distribution Organizations 2019 is estimated to reach $1.4bn in 2024” says Visiongain report

Opportunities in the market stem from the increasing use of specialist and generic drugs, which have higher profit margins; global expansion into the emerging markets; vertical integration of wholesalers; and the increasing use of pharmaceuticals.

28 June 2019

READ

“Global Vaccines Sales market set to grow to $75bn by 2024” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.

25 June 2019

READ

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.

21 June 2019

READ

Categories

Category